Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Michael Birrer to Gene Expression Regulation, Neoplastic

This is a "connection" page, showing publications Michael Birrer has written about Gene Expression Regulation, Neoplastic.

 
Connection Strength
  
 
 
3.545
  
  1. Leaner VD, Chick JF, Donninger H, Linniola I, Mendoza A, Khanna C, Birrer MJ. Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma. Am J Pathol. 2009 Jan; 174(1):265-75.
    View in: PubMed
    Score: 0.242
  2. Wamunyokoli FW, Bonome T, Lee JY, Feltmate CM, Welch WR, Radonovich M, Pise-Masison C, Brady J, Hao K, Berkowitz RS, Mok S, Birrer MJ. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):690-700.
    View in: PubMed
    Score: 0.198
  3. Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, Birrer MJ. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res. 2003 Oct 15; 9(13):4811-8.
    View in: PubMed
    Score: 0.169
  4. Chi RA, van der Watt P, Wei W, Birrer MJ, Leaner VD. Inhibition of Kpn?1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer. BMC Cancer. 2021 Feb 02; 21(1):106.
    View in: PubMed
    Score: 0.140
  5. Sabichi AL, Hendricks DT, Bober MA, Birrer MJ. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst. 1998 Apr 15; 90(8):597-605.
    View in: PubMed
    Score: 0.115
  6. Smith LM, Birrer MJ. Use of transcription factors as agents and targets for drug development. Oncology (Williston Park). 1996 Oct; 10(10):1532-8; discussion 1541-2.
    View in: PubMed
    Score: 0.104
  7. Sabichi AL, Birrer MJ. Regulation of nuclear oncogenes expressed in lung cancer cell lines. J Cell Biochem Suppl. 1996; 24:218-27.
    View in: PubMed
    Score: 0.098
  8. Vathipadiekal V, Wang V, Wei W, Waldron L, Drapkin R, Gillette M, Skates S, Birrer M. Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. Clin Cancer Res. 2015 Nov 01; 21(21):4960-9.
    View in: PubMed
    Score: 0.094
  9. Wei W, Dizon D, Vathipadiekal V, Birrer MJ. Ovarian cancer: genomic analysis. Ann Oncol. 2013 Dec; 24 Suppl 10:x7-15.
    View in: PubMed
    Score: 0.085
  10. Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G, Birrer MJ. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest. 2013 Oct; 123(10):4435-48.
    View in: PubMed
    Score: 0.084
  11. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, K?bel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levine DA, Meyerson M. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013 Jan; 123(1):517-25.
    View in: PubMed
    Score: 0.080
  12. Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C, Theodorescu D, Lee JK. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS One. 2012; 7(2):e30550.
    View in: PubMed
    Score: 0.075
  13. Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, Birrer MJ. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One. 2012; 7(1):e29079.
    View in: PubMed
    Score: 0.075
  14. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 2011; 6(7):e21121.
    View in: PubMed
    Score: 0.072
  15. Helland ?, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ, Pearson RB, B?rresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One. 2011 Apr 13; 6(4):e18064.
    View in: PubMed
    Score: 0.071
  16. Emmanuel C, Gava N, Kennedy C, Balleine RL, Sharma R, Wain G, Brand A, Hogg R, Etemadmoghadam D, George J, Birrer MJ, Clarke CL, Chenevix-Trench G, Bowtell DD, Harnett PR, deFazio A. Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. PLoS One. 2011 Mar 15; 6(3):e17617.
    View in: PubMed
    Score: 0.071
  17. Annunziata CM, Birrer MJ. CD157 in ovarian carcinoma: how does it help us? J Natl Cancer Inst. 2010 Aug 04; 102(15):1104-5.
    View in: PubMed
    Score: 0.067
  18. Na YJ, Farley J, Zeh A, del Carmen M, Penson R, Birrer MJ. Ovarian cancer: markers of response. Int J Gynecol Cancer. 2009 Dec; 19 Suppl 2:S21-9.
    View in: PubMed
    Score: 0.065
  19. van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, Birrer MJ, Leaner VD. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer. 2009 Apr 15; 124(8):1829-40.
    View in: PubMed
    Score: 0.062
  20. Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF, Siu NS, Wong YM, Tsang PT, Pang MW, Yu MY, To KF, Mok SC, Wang VW, Li C, Cheung AY, Doran G, Birrer MJ, Smith DI, Wong YF. Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer. 2009 Mar 15; 124(6):1358-65.
    View in: PubMed
    Score: 0.061
  21. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008 Dec 18; 359(25):2641-50.
    View in: PubMed
    Score: 0.060
  22. Arora S, Wang Y, Jia Z, Vardar-Sengul S, Munawar A, Doctor KS, Birrer M, McClelland M, Adamson E, Mercola D. Egr1 regulates the coordinated expression of numerous EGF receptor target genes as identified by ChIP-on-chip. Genome Biol. 2008; 9(11):R166.
    View in: PubMed
    Score: 0.060
  23. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC, Boyd J, Birrer MJ. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008 Jul 01; 68(13):5478-86.
    View in: PubMed
    Score: 0.059
  24. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, DeMichele A, Huang Q, B?tzow R, Rustgi AK, Weber BL, Birrer MJ, Hatzigeorgiou AG, Croce CM, Coukos G. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A. 2008 May 13; 105(19):7004-9.
    View in: PubMed
    Score: 0.058
  25. Farley J, Ozbun LL, Birrer MJ. Genomic analysis of epithelial ovarian cancer. Cell Res. 2008 May; 18(5):538-48.
    View in: PubMed
    Score: 0.058
  26. Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6880-8.
    View in: PubMed
    Score: 0.048
  27. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6422-30.
    View in: PubMed
    Score: 0.048
  28. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005 Sep 01; 11(17):6300-10.
    View in: PubMed
    Score: 0.048
  29. Farley JH, Birrer MJ. Biologic directed therapies in gynecologic oncology. Curr Oncol Rep. 2003 Nov; 5(6):459-67.
    View in: PubMed
    Score: 0.042
  30. Dent P, Qiao L, Gilfor D, Birrer M, Grant S, Fisher PB. The regulation of tumor suppressor genes by oncogenes. Methods Mol Biol. 2003; 222:269-92.
    View in: PubMed
    Score: 0.040
  31. Huang D, Chowdhury S, Wang H, Savage SR, Ivey RG, Kennedy JJ, Whiteaker JR, Lin C, Hou X, Oberg AL, Larson MC, Eskandari N, Delisi DA, Gentile S, Huntoon CJ, Voytovich UJ, Shire ZJ, Yu Q, Gygi SP, Hoofnagle AN, Herbert ZT, Lorentzen TD, Calinawan A, Karnitz LM, Weroha SJ, Kaufmann SH, Zhang B, Wang P, Birrer MJ, Paulovich AG. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Rep Med. 2021 12 21; 2(12):100471.
    View in: PubMed
    Score: 0.037
  32. Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, Starr TK, Birrer MJ, Paulovich AG. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021 11; 40(46):6395-6405.
    View in: PubMed
    Score: 0.037
  33. Gardner GJ, Birrer MJ. Ovarian tumors of low malignant potential: Can molecular biology solve this enigma? J Natl Cancer Inst. 2001 Aug 01; 93(15):1122-3.
    View in: PubMed
    Score: 0.036
  34. Rinehart-Kim J, Johnston M, Birrer M, Bos T. Alterations in the gene expression profile of MCF-7 breast tumor cells in response to c-Jun. Int J Cancer. 2000 Oct 15; 88(2):180-90.
    View in: PubMed
    Score: 0.034
  35. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999 Oct 28; 18(44):6063-70.
    View in: PubMed
    Score: 0.032
  36. Yeung TL, Leung CS, Yip KP, Sheng J, Vien L, Bover LC, Birrer MJ, Wong STC, Mok SC. Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer. Clin Cancer Res. 2019 11 01; 25(21):6417-6428.
    View in: PubMed
    Score: 0.031
  37. Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, Weening D, Itamochi H, Kluin RJC, Reyners AKL, Birrer MJ, Salvesen HB, Vergote I, van Nieuwenhuysen E, Brenton J, Braicu EI, Kupryjanczyk J, Spiewankiewicz B, Mittempergher L, Bernards R, van der Zee AGJ, de Jong S. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. Clin Cancer Res. 2018 08 15; 24(16):3928-3940.
    View in: PubMed
    Score: 0.029
  38. Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest. 2018 02 01; 128(2):589-606.
    View in: PubMed
    Score: 0.028
  39. Devor EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, Lankes HA, Thaker P, Argenta PA, Pearl ML, Zweizig SL, Mannel RS, Brown A, Ramirez NC, Ioffe OB, Park KJ, Creasman WT, Birrer MJ, Mutch D, Leslie KK. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 12; 147(3):648-653.
    View in: PubMed
    Score: 0.028
  40. Hendricks DT, Taylor R, Reed M, Birrer MJ. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res. 1997 Jun 01; 57(11):2112-5.
    View in: PubMed
    Score: 0.027
  41. Hall KL, Teneriello MG, Taylor RR, Lemon S, Ebina M, Linnoila RI, Norris JH, Park RC, Birrer MJ. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas. Gynecol Oncol. 1997 May; 65(2):330-5.
    View in: PubMed
    Score: 0.027
  42. Birrer MJ. Discoveries in the cell cycle and ovarian cancer. Gynecol Oncol. 1997 Feb; 64(2):187-8.
    View in: PubMed
    Score: 0.027
  43. Parker MF, Arroyo GF, Geradts J, Sabichi AL, Park RC, Taylor RR, Birrer MJ. Molecular characterization of adenocarcinoma of the cervix. Gynecol Oncol. 1997 Feb; 64(2):242-51.
    View in: PubMed
    Score: 0.027
  44. Sosulski A, Horn H, Zhang L, Coletti C, Vathipadiekal V, Castro CM, Birrer MJ, Nagano O, Saya H, Lage K, Donahoe PK, P?pin D. CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis. PLoS One. 2016; 11(6):e0156595.
    View in: PubMed
    Score: 0.025
  45. Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun. 2014 Oct 03; 5:5092.
    View in: PubMed
    Score: 0.023
  46. Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DSL, Mills GB, Sood A, Lee JS. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Res. 2014 Feb; 34(2):811-817.
    View in: PubMed
    Score: 0.022
  47. Levanon K, Sapoznik S, Bahar-Shany K, Brand H, Shapira-Frommer R, Korach J, Hirsch MS, Roh MH, Miron A, Liu JF, Vena N, Ligon AH, Fotheringham S, Bailey D, Flavin RJ, Birrer MJ, Drapkin RI. FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis. Oncogene. 2014 Aug 28; 33(35):4424-32.
    View in: PubMed
    Score: 0.021
  48. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, Birrer MJ. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 1993 Jul 01; 53(13):3103-8.
    View in: PubMed
    Score: 0.021
  49. Sabichi AL, Birrer MJ. The molecular biology of lung cancer: application to early detection and prevention. Oncology (Williston Park). 1993 Jun; 7(6):19-26; discussion 31-2, 37.
    View in: PubMed
    Score: 0.021
  50. Ganzfried BF, Riester M, Haibe-Kains B, Risch T, Tyekucheva S, Jazic I, Wang XV, Ahmadifar M, Birrer MJ, Parmigiani G, Huttenhower C, Waldron L. curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database (Oxford). 2013; 2013:bat013.
    View in: PubMed
    Score: 0.020
  51. Goode EL, DeRycke M, Kalli KR, Oberg AL, Cunningham JM, Maurer MJ, Fridley BL, Armasu SM, Serie DJ, Ramar P, Goergen K, Vierkant RA, Rider DN, Sicotte H, Wang C, Winterhoff B, Phelan CM, Schildkraut JM, Weber RP, Iversen E, Berchuck A, Sutphen R, Birrer MJ, Hampras S, Preus L, Gayther SA, Ramus SJ, Wentzensen N, Yang HP, Garcia-Closas M, Song H, Tyrer J, Pharoah PP, Konecny G, Sellers TA, Ness RB, Sucheston LE, Odunsi K, Hartmann LC, Moysich KB, Knutson KL. Inherited variants in regulatory T cell genes and outcome of ovarian cancer. PLoS One. 2013; 8(1):e53903.
    View in: PubMed
    Score: 0.020
  52. Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 2013 Feb 15; 19(4):809-20.
    View in: PubMed
    Score: 0.020
  53. Sethi G, Pathak HB, Zhang H, Zhou Y, Einarson MB, Vathipadiekal V, Gunewardena S, Birrer MJ, Godwin AK. An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. PLoS One. 2012; 7(10):e47086.
    View in: PubMed
    Score: 0.020
  54. Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, Hua X, Landen CN, Birrer MJ, S?nchez-Beato M, Zhang R. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol Cancer Res. 2012 Nov; 10(11):1462-72.
    View in: PubMed
    Score: 0.020
  55. Barrett J, Birrer MJ, Kato GJ, Dosaka-Akita H, Dang CV. Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells. Mol Cell Biol. 1992 Jul; 12(7):3130-7.
    View in: PubMed
    Score: 0.019
  56. Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature. 1991 Dec 12; 354(6353):494-6.
    View in: PubMed
    Score: 0.019
  57. Li H, Bitler BG, Vathipadiekal V, Maradeo ME, Slifker M, Creasy CL, Tummino PJ, Cairns P, Birrer MJ, Zhang R. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila). 2012 Mar; 5(3):484-91.
    View in: PubMed
    Score: 0.019
  58. McCann CK, Growdon WB, Kulkarni-Datar K, Curley MD, Friel AM, Proctor JL, Sheikh H, Deyneko I, Ferguson JA, Vathipadiekal V, Birrer MJ, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Macdougall JR, Rueda BR. Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. PLoS One. 2011; 6(11):e28077.
    View in: PubMed
    Score: 0.019
  59. Hagemann AR, Cadungog M, Hagemann IS, Hammond R, Adams SF, Chu CS, Rubin SC, Zhang L, Addya K, Birrer MJ, Gimotty PA, Coukos G. Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment. Cancer Biol Ther. 2011 Aug 15; 12(4):357-66.
    View in: PubMed
    Score: 0.018
  60. Hagemann AR, Hagemann IS, Cadungog M, Hwang WT, Patel P, Lal P, Hammond R, Gimotty PA, Chu CS, Rubin SC, Birrer MJ, Powell DJ, Feldman MD, Coukos G. Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. Cancer Biol Ther. 2011 Aug 15; 12(4):367-77.
    View in: PubMed
    Score: 0.018
  61. Bitler BG, Nicodemus JP, Li H, Cai Q, Wu H, Hua X, Li T, Birrer MJ, Godwin AK, Cairns P, Zhang R. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res. 2011 Oct 01; 71(19):6184-94.
    View in: PubMed
    Score: 0.018
  62. King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, Mok SC, Gershenson DM, Wong KK. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am J Surg Pathol. 2011 Jun; 35(6):904-12.
    View in: PubMed
    Score: 0.018
  63. Konstantinopoulos PA, Cannistra SA, Fountzilas H, Culhane A, Pillay K, Rueda B, Cramer D, Seiden M, Birrer M, Coukos G, Zhang L, Quackenbush J, Spentzos D. Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PLoS One. 2011 Mar 29; 6(3):e18202.
    View in: PubMed
    Score: 0.018
  64. Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res. 2011 Apr 15; 17(8):2538-48.
    View in: PubMed
    Score: 0.018
  65. Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, Berkowitz RS, Mok SC. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol Oncol. 2010 Oct; 119(1):114-20.
    View in: PubMed
    Score: 0.017
  66. Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, Ligon AH, Birrer MJ, Drapkin R. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia. 2010 Feb; 12(2):161-72.
    View in: PubMed
    Score: 0.016
  67. Wang B, Khachigian LM, Esau L, Birrer MJ, Zhao X, Parker MI, Hendricks DT. A key role for early growth response-1 and nuclear factor-kappaB in mediating and maintaining GRO/CXCR2 proliferative signaling in esophageal cancer. Mol Cancer Res. 2009 May; 7(5):755-64.
    View in: PubMed
    Score: 0.016
  68. Calvisi DF, Donninger H, Vos MD, Birrer MJ, Gordon L, Leaner V, Clark GJ. NORE1A tumor suppressor candidate modulates p21CIP1 via p53. Cancer Res. 2009 Jun 01; 69(11):4629-37.
    View in: PubMed
    Score: 0.016
  69. Minna JD, Sch?tte J, Viallet J, Thomas F, Kaye FJ, Takahashi T, Nau M, Whang-Peng J, Birrer M, Gazdar AF. Transcription factors and recessive oncogenes in the pathogenesis of human lung cancer. Int J Cancer Suppl. 1989; 4:32-4.
    View in: PubMed
    Score: 0.015
  70. Lorenzi PL, Llamas J, Gunsior M, Ozbun L, Reinhold WC, Varma S, Ji H, Kim H, Hutchinson AA, Kohn EC, Goldsmith PK, Birrer MJ, Weinstein JN. Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther. 2008 Oct; 7(10):3123-8.
    View in: PubMed
    Score: 0.015
  71. Allen NP, Donninger H, Vos MD, Eckfeld K, Hesson L, Gordon L, Birrer MJ, Latif F, Clark GJ. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene. 2007 Sep 13; 26(42):6203-11.
    View in: PubMed
    Score: 0.013
  72. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res. 2007 Feb 15; 67(4):1757-68.
    View in: PubMed
    Score: 0.013
  73. Tsuda H, Bandera CA, Birrer MJ, Hashiguchi Y, Berkowitz RS, Mok SC. Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. Oncology. 2004; 67(3-4):291-9.
    View in: PubMed
    Score: 0.011
  74. Quong J, Eppenberger-Castori S, Moore D, Scott GK, Birrer MJ, Kueng W, Eppenberger U, Benz CC. Age-dependent changes in breast cancer hormone receptors and oxidant stress markers. Breast Cancer Res Treat. 2002 Dec; 76(3):221-36.
    View in: PubMed
    Score: 0.010
  75. Fan M, Goodwin ME, Birrer MJ, Chambers TC. The c-Jun NH(2)-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine. Cancer Res. 2001 Jun 01; 61(11):4450-8.
    View in: PubMed
    Score: 0.009
  76. Ebina M, Mart?nez A, Birrer MJ, Ilona Linnoila R. In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers. Oncogene. 2001 May 03; 20(20):2579-86.
    View in: PubMed
    Score: 0.009
  77. Grant S, Freemerman AJ, Birrer MJ, Martin HA, Turner AJ, Szabo E, Chelliah J, Jarvis WD. Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67). Cell Growth Differ. 1996 May; 7(5):603-13.
    View in: PubMed
    Score: 0.006
  78. Chen TK, Smith LM, Gebhardt DK, Birrer MJ, Brown PH. Activation and inhibition of the AP-1 complex in human breast cancer cells. Mol Carcinog. 1996 Mar; 15(3):215-26.
    View in: PubMed
    Score: 0.006
  79. Domann FE, Levy JP, Birrer MJ, Bowden GT. Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth Differ. 1994 Jan; 5(1):9-16.
    View in: PubMed
    Score: 0.005
  80. Bliss DP, Battey JF, Linnoila RI, Birrer MJ, Gazdar AF, Johnson BE. Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines. J Natl Cancer Inst. 1990 Feb 21; 82(4):305-10.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.